Clinical Trial Update: TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light [Phase 1]

View source ↗

Summary

Phase 1 study in healthy volunteers to evaluate whether TMC435 increases sensitivity of the skin to sunlight; the trial is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• TMC435

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Hepatitis C Virus | Phase 1 | Status: COMPLETED